SG Spiro
-
- Lung Cancer Treatments and Mutations 8
- Chronic Obstructive Pulmonary Disease (COPD) Research 4
- Inhalation and Respiratory Drug Delivery 3
- Oncology top 5%
- Lung Cancer Research Studies 15
- Physiology top 5%
- Epidemiology top 10%
- Neuroendocrine Tumor Research Advances 13
- Endocrine and Autonomic Systems top 10%
-
- Cancer therapeutics and mechanisms 8
-
- Pharmacological Effects and Assays 3
-
- Myasthenia Gravis and Thymoma 3
SG Spiro
45 papers receiving 1.6k citations
Peers
Comparison fields: 5 of 111
- Pulmonary and Respiratory Medicine 813
- Oncology 640
- Physiology 457
- Epidemiology 398
- Endocrine and Autonomic Systems 76
Countries citing papers authored by SG Spiro
This map shows the geographic impact of SG Spiro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by SG Spiro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites SG Spiro more than expected).
Fields of papers citing papers by SG Spiro
This network shows the impact of papers produced by SG Spiro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by SG Spiro. The network helps show where SG Spiro may publish in the future.
Co-authorship network
The 25 scholars most cited alongside SG Spiro, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2008 | 48 | |
| 2 | A phase III randomised, double blind, placebo controlled trial of etoposide/carboplatin with or without thalidomide in advanced small cell lung cancer (SCLC) | 2007 | 6 |
| 3 | The big lung trial (BLT): Determining the value of cisplatin- based chemotherapy for all patients with non-small cell lung cancer (NSCLC). Preliminary results in the supportive care setting | 2002 | 43 |
| 4 | Phase III randomised comparison of gemcitabine and carboplatin (GC) with mitomycin, ifosfamide and cisplatin (MIP) in advanced non-small cell lung cancer (NSCLC) | 2002 | 21 |
| 5 | 2001 | 73 | |
| 6 | 1997 | 143 | |
| 7 | 1996 | 20 | |
| 8 | 1995 | 23 | |
| 9 | 1994 | 10 | |
| 10 | 1994 | 40 | |
| 11 | 1994 | 3 | |
| 12 | 1992 | 38 | |
| 13 | 1991 | 39 | |
| 14 | 1990 | 21 | |
| 15 | 1990 | 67 | |
| 16 | 1989 | 10 | |
| 17 | 1989 | 39 | |
| 18 | 1984 | 1 | |
| 19 | 1975 | 23 | |
| 20 | 1971 | 11 |
About SG Spiro
SG Spiro is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Epidemiology, Neurology and Anesthesiology and Pain Medicine, having authored 46 papers that have together received 1.7k indexed citations. Recurring topics across this work include Lung Cancer Research Studies (15 papers), Neuroendocrine Tumor Research Advances (13 papers), Cancer therapeutics and mechanisms (8 papers), Lung Cancer Treatments and Mutations (8 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (4 papers), Pharmacological Effects and Assays (3 papers), Myasthenia Gravis and Thymoma (3 papers) and Inhalation and Respiratory Drug Delivery (3 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (813 citations), Oncology (640 citations), Physiology (457 citations), Epidemiology (398 citations) and Endocrine and Autonomic Systems (76 citations). SG Spiro has collaborated with scholars based in United Kingdom, United States and Switzerland. Frequent co-authors include John Efthimiou, Carlos Augusto Gomes, J Fleming, R L Souhami, J S Tobias, P. Harper, W R McNabb, John Newsom–Davis, Giles Elrington and N.M.F. Murray. Their work appears in journals such as Thorax, British Journal of Cancer, European Respiratory Journal, British Journal of Clinical Pharmacology and Journal of Clinical Pathology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.